The effect of body weight on the medicine concentrations of dabigatran,edoxaban, apixaban and rivaroxaban in blood.
- Conditions
- DOAC, body weight, trough concentrationDOAC, lichaamsgewicht, dalspiegel
- Registration Number
- NL-OMON22392
- Lead Sponsor
- Haga Teaching Hospital and Central Hospital Pharmacy The Hague
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
Male or female ≥ 18 years
- Treated with a DOAC (rivaroxaban, dabigatran, apixaban, edoxaban) in a therapeutic or prophylactic dosage for at least 5 days
Exclusion Criteria
- The use of relevant co-medication: Ketoconazole, Posaconazole, Voricanazole , Itraconazole , Fluconazole, HIV protease inhibitors, Ticagrelor , Verapamil , Diltiazem (except dabigatran) , Amiodarone , Quinidine, Cyclosporin, Tacrolimus, Clarithromycin, Erythromycin, Carbamazepine, Rifampicin, St John¡¯s wort, Phenytoin
phenobarbital
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective of this study is to investigate the effect of body weight on the trough concentrations of DOACs.
- Secondary Outcome Measures
Name Time Method - To investigate the effect of body weight on anti-Factor Xa (FXa) activity for apixaban, rivaroxaban and edoxaban. <br /><br>- To investigate the effect of body weight on anti-Factor IIa (FIIa) activity for dabigatran.<br>